Your browser doesn't support javascript.
loading
Stasis Dermatitis: The Burden of Disease, Diagnosis, and Treatment.
Yosipovitch, Gil; Jackson, J Mark; Nedorost, Susan T; Friedman, Adam J; Adiri, Roni; Cha, Amy; Canosa, Juliana M.
Afiliação
  • Yosipovitch G; From the Miami Itch Center, Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • Jackson JM; Division of Dermatology, University of Louisville, Louisville, Kentucky, USA.
  • Nedorost ST; Department of Dermatology, University Hospitals of Cleveland, Cleveland, Ohio, USA.
  • Friedman AJ; George Washington School of Medicine and Health Sciences, Washington, District of Columbia, USA.
  • Adiri R; Pfizer Pharmaceuticals Ltd., Herzliya Pituah, Israel.
  • Cha A; Pfizer Inc., New York, New York, USA.
  • Canosa JM; Pfizer Brasil Ltda., São Paulo, Brazil.
Dermatitis ; 2023 Sep 29.
Article em En | MEDLINE | ID: mdl-37782143
ABSTRACT
Stasis dermatitis (SD), an inflammatory dermatosis occurring on the lower extremities, is a cutaneous manifestation of chronic venous insufficiency (CVI). SD is associated with a significant burden of disease. Symptoms such as pain, swelling, and itching can be debilitating for patients, leading to poor sleep, loss of mobility, and the inability to perform daily activities, and can interfere with work and leisure activities. Moreover, SD is a progressive disease with serious secondary complications such as ulcerations, which increase the patients' morbidity, reduce their quality of life, and increase health care burden. Challenges in diagnosing patients may have both short- and long-term sequalae for the patients due to unnecessary treatment and management. In addition, misdiagnosis may result in hospitalizations, placing additional burden on health care professionals in terms of time and financial burden on the health care system. Compression therapy and leg elevation represent the mainstay of treatment for CVI; however, it is also difficult to self-manage, which places a substantial burden on patients and caregivers. Moreover, compression therapy may cause discomfort and exacerbate itching. Subsequent nonadherence may result in disease progression that places additional burden on the physicians who manage these patients and the health care system in terms of resources required and costs incurred. A large proportion of patients with SD develop allergic contact dermatitis because of innate immune signals and altered skin barrier predisposing to sensitization to topical prescriptions, over-the-counter medications, and compression devices used to treat SD. Other than topical corticosteroids, there are no approved pharmacological options to treat inflammation in SD.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article